FindTrial
Sign In

A single-center, prospective, cohort study aimed at evaluating the clinical efficacy of fariciclib injection in patients with newly diagnosed diabetic macular edema (DME)

A single-center, prospective, cohort study aimed at evaluating the clinical efficacy of fariciclib injection in patients with newly diagnosed diabetic macular edema (DME)

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500114532
Enrollment
Unknown
Registered
2025-12-15
Start date
2025-12-20
Completion date
Unknown
Last updated
2026-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic macular edema

Interventions

Observation group:N/A

Sponsors

Xiangya Hospital of Central South University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Age>18 years old, gender not limited; 2. Meets DME related diagnostic criteria ; 3. Has not received intravitreal injection therapy in the past; 4. Be informed and sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1.Combining other eye diseases or macular edema caused by other reasons; 2.Merge other organic diseases of the heart, liver, and kidney, malignant tumors, and leukemia; 3.Patients with eye or periocular infections; 4.Patients with active intraocular inflammation; 5.Patients who are known to be allergic to Fariximab or any excipients; 6.Other situations that researchers consider inappropriate.

Design outcomes

Primary

MeasureTime frame
Best corrected visual acuity;Subretinal Fluid;Intraretinal Fluid;Central Subfield Thickness;—

Countries

China

Contacts

Public ContactZheng Wei

Xiangya Hospital of Central South University

zhengweixy@126.com+86 134 6751 6781

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026